Heli Shang

机构：Shandong Provincial QianFoShan Hospital, Shandong First Medical University · ORCID：0000-0001-8057-1206

发表论文 8 篇 · 总被引 77 次 · h-index 5

代表论文

• NOD2 maybe a biomarker for the survival of kidney cancer patients (2017 · Oncotarget · 被引 26)
• The Association Between the Incidence Risk of Peripheral Neuropathy and PD-1/PD-L1 Inhibitors in the Treatment for Solid Tumor Patients: A Systematic Review and Meta-Analysis (2019 · Frontiers in Oncology · 被引 17)
• Risk associated with central catheters for malignant tumor patients: a systematic review and meta-analysis (2018 · Oncotarget · 被引 16)
• Significance of CD8+ T cell infiltration-related biomarkers and the corresponding prediction model for the prognosis of kidney renal clear cell carcinoma (2021 · Aging · 被引 9)
• Risk of Rash in PD-1 or PD-L1-Related Cancer Clinical Trials: A Systematic Review and Meta-Analysis (2022 · Journal of Oncology · 被引 8)
• The overall safety evaluation of programmed cell death/programmed cell death ligand 1 (PD-1/PD-L1) treatment for lung cancer patients (2019 · Medicine · 被引 1)